secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amneal Pharmaceuticals, Inc. (AMRX)
CIK:        0001723128
Form:       8-K
Filed at:   2026-01-13T23:59:59+00:00
Accession:  0001723128-26-000003
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Amneal expects to meet or exceed FY2025 guidance; net leverage improves to 3.6x
-------------------------------------------------------------------------------

- Net revenue guidance $3.0B-$3.1B; Adj EBITDA $675M-$685M; Adj diluted EPS $0.75-$0.80.
- Operating cash flow guided at $300M-$330M; capex ~$100M
- Net leverage estimated at 3.6x as of Dec 31, 2025, down from 3.9x at Dec 31, 2024.
- Company reaffirms guidance originally provided on Oct 30, 2025; expects to meet or exceed targets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1723128/000172312826000003/0001723128-26-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1723128/000172312826000003/amrx-20260113.htm
  HTML page:      https://secwatch.observer/filing/0001723128-26-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer